Detalhe da pesquisa
1.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Ann Oncol
; 35(5): 429-436, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369015
2.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Ann Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729566
3.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Ann Oncol
; 33(6): 616-627, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337972
4.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol
; 33(4): 384-394, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35093516
5.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Ann Oncol
; 32(8): 994-1004, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34219000
6.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol
; 32(9): 1148-1156, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34116144
7.
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Ann Oncol
; 32(6): 746-756, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741442
8.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Ann Oncol
; 32(12): 1571-1581, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656740
9.
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Ann Oncol
; 31(12): 1709-1718, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946924
10.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 397-404, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30475950
11.
One-year parasitological screening of stray dogs and cats in County Dublin, Ireland.
Parasitology
; 146(6): 746-752, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561289
12.
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Ann Oncol
; 29(3): 640-645, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29236940
13.
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Ann Oncol
; 29(8): 1763-1770, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29878040
14.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718092
15.
Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
Ann Oncol
; 33(2): 227-228, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756989
16.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Ann Oncol
; 28(2): 313-320, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27803006
17.
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Ann Oncol
; 28(11): 2866-2873, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945887
18.
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Ann Oncol
; 27(1): 106-13, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26504153
19.
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Ann Oncol
; 26(4): 688-695, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25542926
20.
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Ann Oncol
; 30(6): 1019, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624581